Chemotherapy is the most common treatment option for both early and advanced cancers. However, drug resistance severely reduces the efficacy of conventional chemotherapeutics and novel biological agents, which constitutes a major obstacle in the treatment of cancer. According to the correlations observed between non-coding RNA (ncRNA) dysregulation and cancer development, it is reasonable to expect that specific tumor-associated ncRNAs will be employed as clinical biomarkers in the near future. The functional analysis of specific ncRNAs indicates that manipulating ncRNAs, either alone or in combination with currently available treatments, is a potential strategy for developing effective personalized therapy regimens.
Although it has been shown that ncRNAs play an important role in cancer development and progression, the molecular mechanisms underlying the mode of action of the vast majority of ncRNAs in cancer development need to be further clarified. As a result, it will be critical to thoroughly explain these processes and identify those ncRNAs that are most relevant to cancer pathobiology. Some of these ncRNAs may be used as therapeutic agents or as reliable biomarkers to detect or pursue cancer development and progression. So far, several ncRNAs have been shown to be capable of altering chemoresistance of cancer cells by influencing DNA repair mechanisms, drug metabolism, apoptosis and epithelial-to-mesenchymal transition processes. Moreover, mounting evidence suggests that ncRNA profiling can help with cancer diagnosis, prognosis, and therapy prediction. This suggests the possibility of integrating ncRNA data into clinical trials to confirm their use.
The purpose of this Research Topic is to bring together a series of articles (both original research and reviews) on recent advances in the impact of ncRNAs on therapy resistance in cancer and to highlight the broadening of our current understanding of the role of ncRNAs in cancer and their impact on signaling pathways. Besides, manuscripts discussing state-of-the-art ncRNA technologies and developments in diagnostics and therapeutics of ncRNAs are invited as well.
Chemotherapy is the most common treatment option for both early and advanced cancers. However, drug resistance severely reduces the efficacy of conventional chemotherapeutics and novel biological agents, which constitutes a major obstacle in the treatment of cancer. According to the correlations observed between non-coding RNA (ncRNA) dysregulation and cancer development, it is reasonable to expect that specific tumor-associated ncRNAs will be employed as clinical biomarkers in the near future. The functional analysis of specific ncRNAs indicates that manipulating ncRNAs, either alone or in combination with currently available treatments, is a potential strategy for developing effective personalized therapy regimens.
Although it has been shown that ncRNAs play an important role in cancer development and progression, the molecular mechanisms underlying the mode of action of the vast majority of ncRNAs in cancer development need to be further clarified. As a result, it will be critical to thoroughly explain these processes and identify those ncRNAs that are most relevant to cancer pathobiology. Some of these ncRNAs may be used as therapeutic agents or as reliable biomarkers to detect or pursue cancer development and progression. So far, several ncRNAs have been shown to be capable of altering chemoresistance of cancer cells by influencing DNA repair mechanisms, drug metabolism, apoptosis and epithelial-to-mesenchymal transition processes. Moreover, mounting evidence suggests that ncRNA profiling can help with cancer diagnosis, prognosis, and therapy prediction. This suggests the possibility of integrating ncRNA data into clinical trials to confirm their use.
The purpose of this Research Topic is to bring together a series of articles (both original research and reviews) on recent advances in the impact of ncRNAs on therapy resistance in cancer and to highlight the broadening of our current understanding of the role of ncRNAs in cancer and their impact on signaling pathways. Besides, manuscripts discussing state-of-the-art ncRNA technologies and developments in diagnostics and therapeutics of ncRNAs are invited as well.
